FDA approves Rybelsus, the first oral GLP-1 receptor agonist proven to lower heart attack and stroke risks in adults with type 2 diabetes at high cardiovascular risk.
- FDA approves first oral GLP-1 agonist to lower heart attack and stroke risk in diabetics
- SOUL trial shows 14% drop in major cardiovascular events with Rybelsus
- Targets arterial inflammation and oxidative stress for lasting heart protection
People living with type 2 diabetes face a heightened risk of heart attack and stroke, but a new pill could change that reality (1✔ ✔Trusted Source
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Go to source
).
In a landmark approval, the U.S. Food and Drug Administration (FDA) has authorized Rybelsus, the first oral GLP-1 receptor agonist, for reducing the risk of major cardiovascular events in adults with type 2 diabetes who have a high risk of heart disease.
Until now, advanced GLP-1–based therapies were available only as injections. Rybelsus brings this protection in pill form, offering a new preventive approach that focuses on inflammation, the hidden trigger behind artery damage and heart disease.
How Rybelsus Protects the Heart Beyond Blood Sugar Control
Rybelsus (oral semaglutide) mimics the natural hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar, insulin release, and appetite.
Its newly recognized cardiovascular benefits stem from its anti-inflammatory and vascular-protective actions:
- Reduces oxidative stress and arterial inflammation, two key causes of atherosclerosis
- Improves endothelial function, keeping blood vessels flexible and healthy
- Makes platelets less sticky, lowering the risk of blood clots
Together, these effects ensure smoother blood flow and prevent plaque buildup, protecting arteries from long-term damage and reducing cardiovascular risk (2✔ ✔Trusted Source
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Go to source
).
The SOUL Trial: Clinical Proof of Cardiovascular Benefit
The FDA’s approval was supported by the pivotal SOUL trial, a large randomized study involving about 9,630 adults with type 2 diabetes and elevated cardiovascular risk. Participants received either Rybelsus or placebo for nearly four years.
Results showed:
- 14% reduction in major adverse cardiovascular events (MACE) including heart attack, stroke, or cardiovascular death
- 12.0% of Rybelsus patients experienced MACE compared to 13.8% on placebo
- 16% lower stroke risk and 10% fewer heart failure hospitalizations
The drug displayed a favorable safety profile, with no significant increase in serious side effects.
A complementary meta-analysis of 20,000 patients confirmed that semaglutide reduces cardiovascular deaths and improves long-term vascular health (3✔ ✔Trusted Source
Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Go to source).
A New Approach to Heart Disease Prevention
Traditional prevention has focused on statins and blood pressure control, but Rybelsus introduces a third target — inflammation.
By calming systemic inflammation, it directly addresses a root cause of artery hardening and blockage. As an oral drug, it enhances treatment convenience and patient adherence, especially among those reluctant to use injections.
Patients should take Rybelsus on an empty stomach with water, then wait at least 30 minutes before eating or taking other medicines to ensure full absorption. Mild side effects such as nausea or bloating may occur initially but usually ease over time.
Transforming the Future of Diabetes and Heart Care
The FDA’s approval of Rybelsus marks a new chapter in preventive cardiology by combining metabolic control and heart protection.
With cardiovascular disease still the world’s leading cause of death, this therapy could redefine prevention strategies for millions of diabetic adults. Experts believe that by targeting inflammation and glucose imbalance together, Rybelsus bridges the gap between diabetes management and heart health, offering hope for a longer and healthier life.
References:
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight – (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or)
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes – (https://pubmed.ncbi.nlm.nih.gov/40162642/)
- Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials – (https://pubmed.ncbi.nlm.nih.gov/40968407/)
Source-Medindia